Objectives: Many patients with small bowel neuroendocrine tumors (SBNETs) have multifocal tumors (MFTs), but the frequency of MFTs has varied widely across SBNET studies. It is also unclear whether patients with MFTs have more advanced disease or worse clinical course than do those with unifocal SBNETs. We set out to determine the frequency of multifocal and unifocal SBNETs and compare clinicopathologic factors, somatostatin receptor 2 expression, and survival.
S mall bowel neuroendocrine tumors (SBNETs) are generally small, indolent neoplasms most commonly found in the jejunum and ileum. 1 Their incidence has increased greatly since the 1970s, and they are now the most common small bowel malignancy in the United States. 2 They arise from enterochromaffin cells of the small intestine, which comprise approximately 1% of the mucosal cells. 3 Because of their relative rarity and nonspecific clinical symptoms, the average length of time between symptom onset and diagnosis is 9.2 years, and patients are often diagnosed after metastasis to the liver. 4 Despite metastatic disease, patients with SBNETs can still have long-term survival. 5, 6 The clinical presentation of patients with SBNETs may include signs or symptoms of carcinoid syndrome, bowel obstruction, gastrointestinal bleeding, or nonspecific abdominal pain. Unfortunately, few SBNETs are detected when they are at an early stage and potentially curable by resection, and in these cases, tumors are often discovered incidentally, where the patient is being evaluated for something else. 7 Primary SBNETs may be small, yet still present with bulky mesenteric nodal disease and extensive liver metastases. Moertel et al 8 observed that less than 2% of patients with SBNETs of less than 1 cm had metastases, which increased to 50% for those with 1-to 2-cm tumors and 80% for those with more than 2 cm. Soga 9 reported an even higher rate of metastasis, 30%, in gastrointestinal carcinoids of less than 1 cm.
On careful exploration and palpation of the small bowel, many patients with SBNETs are found to have more than 1 tumor, although how this influences metastasis and prognosis in patients is unclear. The frequency of multifocal SBNETs has been reported to range between 13% and 45%. 8, [10] [11] [12] [13] The high variance in reported rates of multifocality may be due to differences in patient populations and whether this was determined intraoperatively or at autopsy. 8 The etiology of multiple tumors remains unsettled, with some authors suggesting that these arise from dissemination through submucosal lymphatics, 14 and others by the development of oligoclonal tumors through field cancerization. 15 Large retrospective studies in breast and lung cancers have shown that tumor multifocality is associated with poorer prognosis, 16, 17 and smaller studies in SBNETs have also suggested that multifocality may be associated with increased tumor aggressiveness. 12, 13 We set out to ascertain the rate of multifocal tumors (MFTs) in patients with SBNETs at a single center and determine whether patients with MFTs had worse outcomes than did patients with solitary SBNETs.
MATERIALS AND METHODS
Patients with SBNETs who had surgical management of their primary and/or metastatic tumors at the University of Iowa between 1999 and 2016 were enrolled into an institutional review board-approved Neuroendocrine Tumor Registry. Clinical information, including operative notes, radiology, pathology, and laboratory testing, was retrieved from the electronic medical record. Demographic information, date of diagnosis, date of first neuroendocrine tumor (NET) surgery, last follow-up, and death were recorded. Clinicopathologic information, including primary tumor size, liver metastases, lymph node metastases, other metastases, Tumor Node Metastasis (TNM) staging, grade, and number of tumors, was collected. Intraoperatively, careful palpation of the small bowel from the ligament of Treitz to the ileocecal valve was carried out, and the location and number of tumors were recorded. Patients were excluded if information was missing regarding inspecting the entire small bowel. If a patient's tumors were multifocal, the largest tumor size was recorded as the primary tumor size. Preoperative and postoperative symptoms such as flushing, diarrhea, abdominal pain, and bronchial symptoms were also documented, as well as preoperative and postoperative biochemical marker levels for serotonin, chromogranin A, and pancreastatin.
Ki-67 Expression and Grading
The majority of tumors were stained for Ki-67 using the MIB-1 antibody, although this was not routinely performed for tumors resected prior to 2010. Areas of high tumor density were identified on the corresponding hematoxylin-eosin-stained slide, and within these areas, a 400Â field containing at least 500 tumor cells with as many Ki-67-positive cells as possible was selected. For samples with fewer tumor cells, the threshold was lowered to 350 cells. All Ki-67-positive and Ki-67-negative tumor cells were counted. Any cells with MIB-1 activity were counted as positive, and cells without staining were considered negative for Ki-67 expression. The Ki-67 index was calculated by dividing the total number of positive cells by the sum of the numbers of positive and negative cells. All samples were graded using the highest Ki-67 index with a modified World Health Organization classification system (G1 Ki-67 = 0%-2%; G2 = >2%-20%; G3 = >20%). 18, 19 When Ki-67 had not been performed, the grade assigned by the pathologist using morphology or mitotic index was recorded.
Somatostatin Receptor 2 Expression
Somatostatin receptor 2 (SSTR2) expression was measured by quantitative polymerase chain reaction (qPCR). Total RNA was isolated from RNAlater-preserved tumor tissue using the Trizol method (Life Technologies, Carlsbad, Calif ) and reverse transcribed to cDNA. Each sample was amplified in triplicate using Taqman reagents (Life Technologies) on StepOne-Plus and 7900 HT-Fast RT-PCR platforms (Life Technologies). GAPDH and POLR2A served as internal controls, and the mean threshold cycle (Ct) of these genes was used to calculate normalized values for the mean SSTR2 threshold cycle (dCt).
Data Analysis
Data were exported to the software program R (v3.3.1; R Foundation, Vienna, Austria) for analysis. Overall survival (OS) and progression-free survival (PFS) were determined using the KaplanMeier method. Clinicopathologic factors were compared between groups using Welch t-test, Wilcoxon test, and Fisher's exact test.
RESULTS

Clinical Characteristics of Patients With Multifocal and Unifocal Tumors
There were 179 patients who underwent surgical exploration for primary and/or metastatic SBNETs at our institution over this period where details from full exploration of the small bowel were available. Of these, 81 patients (45.3%) had MFTs, and 98 patients (54.7%) had unifocal tumors (UFTs; Table 1 ). The number of primary tumors found during surgical exploration ranged from 2 to 129 tumors in those with MFTs. Forty-three patients had 2 to 5 tumors, 20 had 6 to 10 tumors, 11 had 11 to 20 tumors, and 7 patients had more than 20 tumors (21, 28, 29, 38, 42, 47 , and 129 tumors, respectively). The median number of multifocal primary tumors was 5, and the mean was 9.5 tumors. Overall, 57% of SBNET patients were male, with the multifocal group being slightly more male predominant (63% vs 52% for UFTs), but this difference was not significant (P = 0.17). Patients with MFTs were diagnosed between ages 30.0 and 83.3 years, with a median age at diagnosis of 58.7 years, whereas the age at diagnosis for UFTs ranged from 15.4 to 85.2 years, with a median of 59.4 years (P = 0.69).
Survival
Median PFS was 3.07 years for patients with MFTs and 3.83 years for UFTs, and there was no significant difference between groups (P = 0.57; Fig. 1 ). Median OS was 10.5 years for patients with UFTs and was not reached for those with MFTs. At 5 and 10 years, OS was very similar for those with MFTs as UFTs (P = 0.63; Fig. 2 ).
Tumor Pathology
Median primary tumor size was not significantly different between MFTs and UFTs (1.7 and 2.0 cm, respectively, P = 0.09; Table 2 ). There were also no significant differences in TNM staging. T3/T4 tumors were found in 79.7% of MFT patients and in 78.1% with UFTs (P = 0.85). Nodal metastases were seen in 91.8% of patients with MFTs and 89.1% with UFTs (P = 0.79). Distant metastases were seen in 78.8% of patients with MFTs and 79.8% of those with UFTs (P = 1.00), and hepatic metastases were also equally likely in patients with MFTs versus UFTs (69.1% vs 75.5%, P = 0.40). Other distant, nonhepatic, nonnodal metastases were less common and included lung, peritoneum, ovary, and bone. There was no significant difference in the frequency of these types of metastases for those with MFTs and UFTs (43.2% vs 49%, P = 0.46). In terms of tumor grade, both groups were nearly identical (Table 3 ). Each group contained 1 patient with a grade 3 primary tumor. The remainder were grade 1 or 2, and there was no significant difference in the incidence of grade 1 (P = 0.42) or grade 2 tumors (P = 0.51) between both groups. Ki-67 expression was used to determine World Health Organization grade in approximately half of MFT and UFT patients, and mean Ki-67 expression was found to be similar for both groups (P = 0.46). Finally, the level of SSTR2 expression as determined by qPCR was not significantly different in MFTs versus UFTs (P = 0.59).
Tumor Functionality and Preoperative Laboratory Values
To determine if there were any differences in tumor functionality and tumor secretory product levels in patients with MFTs and UFTs, preoperative symptoms and biochemical markers were analyzed. There was no significant difference in the frequency of functional tumors (P = 0.77), defined as whether patients had symptoms of flushing or diarrhea and elevation of chromogranin A or pancreastatin above the reference range or 2-fold elevation of serotonin (>400 ng/mL, due to increased variability of this marker). There were also no significant differences in the rate of preoperative elevation of biochemical markers above the reference range (or twice normal for serotonin) in MFTs versus UFTs. Pancreastatin was elevated in 75.3% of MFTs versus 79.8% of UFTs (P = 0.56), chromogranin A in 64.3% of MFTs versus 64.2% of UFTs (P = 1.00), and 2-fold elevation of serotonin in 78.7% of MFTs versus 72.7% of UFTs (P = 0.47; Table 4 ). Table 5 ).
DISCUSSION
In one of the earliest and largest studies of carcinoids of the small intestine, Moertel et al 8 reported that 60 (29%) of their 13 reported on the experience from the Armed Forces Institute of Pathology, where they found that 43 (29%) of 167 SBNET patients had MFTs, ranging from 2 to 100 tumors. 16 In an autopsy series from Malmo, Sweden, the incidence of all carcinoid tumors in the population was found to be 1.22%, and 50 (33%) of 152 SBNET cases were multifocal. 10 In a study pooling data from 3 Boston hospitals, Yantiss et al 12 reported 18 (26%) of 68 patients had MFTs, the most numerous having 30 tumors. 15 In Northern Ireland, Watson et al 11 found a lower incidence of MFTs, which were seen in only 7 (12.7%) of 55 SBNET patients, which ranged from 3 to 10 in number. In the current study, we found a higher frequency of MFTs of 45.3% in 179 patients from a single institution, operated on by a single surgeon. This higher rate of detection may be due to a more systematic intraoperative exploration for these tumors, but details on the conduct and consistency of surgical exploration or postmortem examination are limited in these previous studies. Given the high incidence of multifocality and effectiveness of surgical treatment, we believe that careful bimanual palpation of the small bowel during surgery is critical to detect these tumors so that all can be resected. We prefer open exploration with direct bimanual palpation over laparoscopic exploration, because tumors can easily be missed by the latter method when the bowel is palpated using only graspers. Laparoscopy may succeed in identifying larger tumors or those with obvious transserosal extension, but will miss small tumors, which may be only a few millimeters in size. However, a hybrid approach may be reasonable, with laparoscopic exploration but careful digital palpation of the entire jejunum and ileum through a small incision.
While the existence of multifocality has been well established in SBNETs, 8, [10] [11] [12] [13] its effects on tumor biology has not been extensively studied. Burke et al 13 found that having multiple SBNETs was negatively correlated with survival on univariate analysis, but that this was not an independent factor for survival on multivariate analysis. Yantiss et al 12 evaluated numerous clinicopathologic factors and found that SBNET patients with MFTs were significantly younger, more commonly female, and more likely to suffer from carcinoid syndrome; had more advanced tumor stage; and had shorter PFS and OS. The current study was much larger and examined additional clinicopathologic factors, including SSTR2 and Ki-67 expression. We did not find any significant differences between these clinicopathologic factors in the groups with MFTs versus UFTs, and there was also no difference in PFS or OS. We conclude that the tumor characteristics and clinical course of SBNET patients with MFTs is not more aggressive than that seen in patients with UFTs. In other cancers, however, tumor multifocality has been associated with more aggressive disease. Vera-Bradillo et al 16 compared 67,557 women from 22 studies and found that women with multifocal breast tumors have a greater probability of nodal metastasis and relapse, resulting in worse survival than in women with UFTs. Similarly, Arslan et al 17 compared 168 patients with locally advanced non-small cell lung cancer and found that OS in patients with multifocal lung cancer was significantly shorter as compared with those with UFTs. Despite the poorer prognoses for MFTs from these other sites, current TNM staging for SBNETs does not change based on multifocality. The European Neuroendocrine Tumor Society TNM staging classification of midgut and hindgut NETs acknowledges multifocality by adding an "m" to the T stage (T1m, T2m, T3m, T4m). However, only the greatest dimension of the largest tumor is considered, and the "m" designation has no impact on the overall staging category. 19 This seems appropriate, given the lack of survival differences between patients with MFTs versus those with UFTs in this study.
Many patients with SBNETs are treated with somatostatin analogs, by either monthly injection 5, 21 or peptide receptor radionuclide therapy. 22 We found similar levels of expression of SSTR2 in the MFT and UFT groups, and therefore treatment with somatostatin analogs is likely equally useful in patients with MFTs and UFTs. Somatostatin receptor 2 is also an excellent target for imaging. This includes both SRS with indium In 111-labeled somatostatin analog and single-photon emission CT, 23 and gallium Ga 68-labeled somatostatin analog with positron emission tomography. 24, 25 A study by Maxwell et al 23 found that SBNET tumor size 2 cm or less led to significantly reduced tumor detection by SRS.
In the current study, we found that half of the patients in both groups had primary tumors that were 2 cm or less in diameter, and overall, only 27 (50.9%) of 53 in the multifocal group and 29 (50%) of 58 in the unifocal group had positive SRS.
The mechanisms responsible for the high frequency of multifocality in SBNET remain undefined. Unlike the multifocal pancreatic NETs seen in patients with multiple endocrine neoplasia type 1 or Von Hippel Lindau syndrome, familial cases of SBNETs are rare. However, the National Institutes of Health has followed 33 families with multiple members having SBNETs, and the overall incidence of multifocality was 67% (36 of 54 patients, with 2-50 tumors). One large SBNET family was found to have a 4-base-pair germline deletion in the inositol polyphosphate multikinase gene (IPMK), but mutations of IPMK were not found in their other families. 26 Besides a familial predisposition due to an inherited mutation, another explanation for the origin of MFTs in SBNET patients is that tumor growth into lymphatic channels redirects flow and causes submucosal spread of tumor cells along the small bowel. Wang et al 14 felt that this was the explanation for why they saw multiple tumors in patients with more extensive mesenteric nodal disease. Supporting the hypothesis of MFTs arising from a single primary, Guo et al 27 found evidence for monoclonality in separate tumors derived from 4 patients by the finding of nonrandom X chromosome inactivation. Another possibility for the origin of MFTs is that an exogenous growth factor influences specific stem cells to undergo malignant transformation into SBNETs. The development of gastric carcinoids is an example of this type of transformation, where the release of trophic factors (hypergastrinemia) induces the formation of multiple tumors. 15 This could be a mechanism of field cancerization, where both genetic and epigenetic changes accumulate in the small bowel over time, because of environmental exposure and/or even genetic predisposition, resulting in multiple independent tumors. By studying loss of heterozygosity and X chromosome inactivation, Katona et al 15 found evidence for the independent origin of MFTs in 11 (85%) of 13 midgut carcinoid patients. We conclude that the available evidence has not firmly established whether MFTs originate from a single tumor or from multiple, independent primary sites in patients with sporadic SBNETs, but the latter would be the most likely mechanism in cases of familial SBNETs.
In summary, multifocality of SBNETs was higher in this study than previously reported in other large series, being found in almost half of patients having careful surgical exploration. Given this high frequency, we prefer open surgery to allow for thorough bimanual palpation of the small bowel over laparoscopic methods, although the latter may be acceptable, provided the entire small bowel is palpated through a small incision. Small bowel neuroendocrine tumor multifocality was not associated with more aggressive tumor characteristics or reduced patient survival, and therefore MFTs and UFTs can be treated in a similar fashion. Surgical resection remains the optimal treatment of SBNETs, [28] [29] [30] [31] [32] [33] [34] but a more extensive resection may be required for MFTs than UFTs. Comparable rates of SSTR2 expression were found in MFTs and UFTs, suggesting that treatment with somatostatin analogs may be similarly effective. 
